ASCO 2022

Breast Cancer

Sacituzumab govitecan meets primary endpoint 

Presented By

Prof. Hope Rugo, University of California San Francisco, CA, USA

Trial

Phase 3, TROPiCS-02

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:11

Shaky OS results of palbociclib in ER-positive/HER2-negative breast cancer 

Presented By

Prof. Richard Finn, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, PALOMA-2

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:09

Practice-changing results of T-DXd in HER2-low breast cancer 

Presented By

Prof. Shanu Modi, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DESTINY-Breast04

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:04

SET2,3 to inform on chemotherapy decisions in ER-positive breast cancer

Presented By

Dr Otto Metzger, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, CALGB9741

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:59

Metastasis-directed therapy fails in oligometastatic breast cancer

Presented By

Dr Steven Chmura, University of Chicago, IL, USA

Trial

Phase 2, NRG-BR002

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:34

Analysis by residual cancer burden further clarifies effect of pembrolizumab

Presented By

Prof. Lajos Pusztai, Yale School of Medicine, CT, USA

Trial

Phase 3, KEYNOTE-522

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:26

Contribution of metastatic therapies on mortality reduction in breast cancer

Presented By

Prof. Jennifer Caswell-Jin, Stanford University, CA, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:19

Radiotherapy may be omitted in breast cancer patients 

Presented By

Prof. Timothy Whelan, McMaster University, Canada

Trial

LUMINA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 10:59

Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer

Presented By

Prof. Kevin Kalinsky, Winship Cancer Institute of Emory University, GA, USA

Trial

Phase 2, MAINTAIN

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 10:53

7-gene biosignature: Benefits of endocrine therapy and radiotherapy in breast cancer risk groups

Presented By

Dr Pat Whitworth, Nashville Breast Cancer Center, TN, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 10:44

Lung Cancer

Additional tiragolumab does not help patients with untreated small cell lung cancer 

Presented By

Dr Charles Rudin, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, SKYSCRAPER-02

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:42

Success for serplulimab plus chemotherapy in small cell lung cancer

Presented By

Prof. Ying Cheng, Jilin Cancer Hospital, China

Trial

Phase 3, ASTRUM-005

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:38

Adagrasib safe and clinically active in non-small cell lung cancer

Presented By

Dr Alexander Spira, Virginia Cancer Specialists Research Institute, VA, USA

Trial

Phase 2, KRYSTAL-1

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:33

Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer

Presented By

Prof. Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center, Australia

Trial

Phase 3, CheckMate 227

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:29

Effect of KRAS mutations and PD-L1 expression on therapy response in non-small cell lung cancer

Presented By

Dr Oladimeji Akinboro, US Food and Drug Administration, MD, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:26

Melanoma

First results on distant metastasis-free survival in stage II melanoma 

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 3, KEYNOTE-716

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 13:54

Higher response rates for concurrent triple therapy versus sequential therapy in melanoma

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 2, NeoTrio

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 13:50

Genitourinary Cancers

Exploratory treatment options fail in ccRCC 

Presented By

Prof. Thomas Powles, University of London, UK

Trial

Phase 2, CALYPSO

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:18

Adjuvant everolimus did not benefit high-risk renal cell carcinoma 

Presented By

Dr Christopher W. Ryan, Oregon Health & Science University, OR, USA

Trial

Phase 3, EVEREST

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:14

Cabozantinib fails as first-line maintenance therapy in urothelial cancer

Presented By

Prof. Robert Jones, University of Glasgow, UK

Trial

Phase 2, ATLANTIS

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:11

177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC

Presented By

Prof. Michael Hofman, Peter McCallum Cancer Centre, Australia

Trial

Phase 2, TheraP

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:08

Enzalutamide performs well in metastatic hormone-sensitive prostate cancer

Presented By

Prof. Ian Davis, Monash University, Australia

Trial

Phase 3, ENZAMET

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:04

Haematologic Malignancies

Autologous stem cell transplantation plus RVd improves PFS in multiple myeloma  

Presented By

Prof. Paul Richardson, Harvard Medical School, MA, USA

Trial

Phase 3, DETERMINATION

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:33

Novel first-line treatment option for mantle cell lymphoma 

Presented By

Prof. Michael Wang, Anderson Cancer Center, TX, USA

Trial

Phase 3, SHINE

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:30

Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma

Presented By

Prof. Juan Du, Shanghai Chang Zheng Hospital, China

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:24

Gastrointestinal Cancers

Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer  

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 3, PARADIGM

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:19

Spectacular results for dostarlimab in mismatch repair deficient rectal cancer 

Presented By

Dr Andrea Cercek, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:14

Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases

Presented By

Prof. Cornelis Punt, University Medical Center Utrecht, the Netherlands

Trial

Phase 3, CAIRO5

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:11

To resect or not to resect primary tumours in stage IV colon cancer?

Presented By

Prof. Jürgen Weitz, Technische Universität Dresden, Germany

Trial

SYNCHRONOUS

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:08

Novel treatment option for KRAS wildtype pancreatic cancer 

Presented By

Prof. Shukui Qin, Cancer Center of Jinling Hospital, China

Trial

Phase 3, NOTABLE

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:03

Gynaecological Cancers

Primary results of rucaparib in ovarian cancer 

Presented By

Prof. Bradley Monk, University of Arizona, AZ, USA

Trial

Phase 3, ATHENA-MONO

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:28

Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer 

Presented By

Dr Domenica Lorusso, San Raffaele Scientific Institute, Italy

Trial

Phase 3, MIT023

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:25

Encouraging results of relacorilant in ovarian cancer

Presented By

Prof. Nicoletta Colombo, University of Milan, Italy

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:23

Miscellaneous Topics

Bacterial decolonisation effective against radiation dermatitis

Presented By

Ms Yana Kost, Albert Einstein College of Medicine, NY, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:38

New standard-of-care for cisplatin-ineligible locally advanced head and neck squamous cell carcinoma

Presented By

Prof. Vanita Noronha, Tata Memorial Hospital, India

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:35

Ifosfamide is likely to be the go-to therapy in recurrent Ewing sarcoma 

Presented By

Dr Martin McCabe, University of Manchester, UK

Trial

Phase 3, rEECur

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:32

Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma 

Presented By

Prof. Eric Bouffet, University of Toronto, Canada

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:30